Literature DB >> 10456654

Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).

M C Kyrtsonis1, A Mouzaki, A Maniatis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10456654     DOI： 10.1007/bf02785839

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  33 in total

1.  Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

Authors:  A Villunger; A Egle; I Marschitz; M Kos; G Böck; H Ludwig; S Geley; R Kofler; R Greil
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

2.  B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Authors:  A C Rawstron; F E Davies; R G Owen; A English; G Pratt; J A Child; A S Jack; G J Morgan
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

3.  Prophylactic antibiotics for the prevention of early infection in multiple myeloma.

Authors:  M M Oken; C Pomeroy; D Weisdorf; J M Bennett
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

4.  Frequent hypermethylation of p16 and p15 genes in multiple myeloma.

Authors:  M H Ng; Y F Chung; K W Lo; N W Wickham; J C Lee; D P Huang
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

5.  The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance.

Authors:  H Gregersen; K M Madsen; H T Sørensen; H C Schønheyder; J S Ibsen; J F Dahlerup
Journal:  Eur J Haematol       Date:  1998-08       Impact factor: 2.997

6.  Abnormal clonogenic potential of T cells from multiple myeloma patients.

Authors:  L M Pilarski; M J Mant; B A Ruether; G Carayanniotis; D Otto; J F Krowka
Journal:  Blood       Date:  1985-12       Impact factor: 22.113

7.  Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma.

Authors:  M C Kyrtsonis; C Repa; G V Dedoussis; A Mouzaki; A Simeonidis; M Stamatelou; A Maniatis
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

8.  Increased production of interleukin-6 by T lymphocytes from patients with multiple myeloma.

Authors:  P Lapeña; A Prieto; J Garcia-Suarez; E Reyes; J San Miguel; J Jorda; M Alvarez-Mon
Journal:  Exp Hematol       Date:  1996-01       Impact factor: 3.084

9.  Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma.

Authors:  H M Chapel; M Lee; R Hargreaves; D H Pamphilon; A G Prentice
Journal:  Lancet       Date:  1994-04-30       Impact factor: 79.321

10.  Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin.

Authors:  D Amran; H Renz; G Lack; K Bradley; E W Gelfand
Journal:  Clin Immunol Immunopathol       Date:  1994-11
View more
  5 in total

1.  The relationship between hypogammaglobulinemia, monoclonal gammopathy of undetermined significance and humoral immunodeficiency: a case series.

Authors:  Robert Marc Zemble; Patricia A Takach; Arnold I Levinson
Journal:  J Clin Immunol       Date:  2011-06-05       Impact factor: 8.317

Review 2.  Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

Authors:  Nicolò Compagno; Giacomo Malipiero; Francesco Cinetto; Carlo Agostini
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

3.  Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

Authors:  Verónica González-Calle; Seila Cerdá; Jorge Labrador; Eduardo Sobejano; Beatriz González-Mena; Carmen Aguilera; Enrique María Ocio; María Belén Vidriales; Noemí Puig; Norma Carmen Gutiérrez; Ramón García-Sanz; José María Alonso; Rosa López; Carlos Aguilar; Alfonso García de Coca; Roberto Hernández; José Mariano Hernández; Fernando Escalante; María-Victoria Mateos
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

Review 4.  Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sarah M Tete; Marc Bijl; Surinder S Sahota; Nicolaas A Bos
Journal:  Front Immunol       Date:  2014-06-03       Impact factor: 7.561

5.  Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

Authors:  Rasmus Sørrig; Tobias W Klausen; Morten Salomo; Annette J Vangsted; Ulf Christian Frølund; Kristian T Andersen; Anja Klostergaard; Carsten Helleberg; Robert S Pedersen; Per T Pedersen; Sissel Helm-Petersen; Elena Manuela Teodorescu; Birgitte Preiss; Niels Abildgaard; Peter Gimsing
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.